<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>336</serviceExecutionTime><Drug id="8148"><DrugName>PD-143188</DrugName><DrugSynonyms><Name><Value>PD-143188</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CI-1007</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PD-147693</Value><Types><Type>Research Code</Type><Type>Metabolite</Type></Types></Name><Name><Value>PD-149394</Value><Types><Type>Research Code</Type><Type>Metabolite</Type></Types></Name><Name><Value>PD-155144</Value><Types><Type>Research Code</Type><Type>Metabolite</Type></Types></Name><Name><Value>PD-163637</Value><Types><Type>Research Code</Type><Type>Metabolite</Type></Types></Name><Name><Value>PD-163639</Value><Types><Type>Research Code</Type><Type>Metabolite</Type></Types></Name><Name><Value>150013-70-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20805">Parke-Davis &amp; Co</CompanyOriginator><CompaniesSecondary><Company id="20805">Parke-Davis &amp; Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="8148" type="Drug"><TargetEntity id="197585" type="siDrug">PD-143188</TargetEntity></SourceEntity><SourceEntity id="20805" type="Company"><TargetEntity id="5000120321" type="organizationId">Parke Davis &amp; Company LLC</TargetEntity></SourceEntity><SourceEntity id="282" type="ciIndication"><TargetEntity id="10061920" type="MEDDRA"/><TargetEntity id="D011618" type="MeSH"/><TargetEntity id="61" type="siCondition"/></SourceEntity><SourceEntity id="299" type="ciIndication"><TargetEntity id="F20" type="ICD10"/><TargetEntity id="10039626" type="MEDDRA"/><TargetEntity id="D012559" type="MeSH"/><TargetEntity id="-729613619" type="omicsDisease"/><TargetEntity id="65" type="siCondition"/></SourceEntity><SourceEntity id="144" type="Action"><TargetEntity id="129" type="Mechanism">Dopamine Receptor Agonists</TargetEntity><TargetEntity id="759" type="Mechanism">Dopamine Precursors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="282">Psychotic disorder</Indication><Indication id="299">Schizophrenia</Indication></IndicationsSecondary><ActionsPrimary><Action id="144">Dopamine receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2943">Antipsychotic</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N5A</Code><Name>ANTIPSYCHOTICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-09-04T04:22:11.000Z</LastModificationDate><ChangeDateLast>2002-05-09T15:15:52.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="8148" linkType="Drug"&gt;PD-143188&lt;/ulink&gt; (CI-1007) is a dopamine autoreceptor agonist that was in phase II clinical trials by Parke-Davis as an antipsychotic agent [&lt;ulink linkID="167848" linkType="reference"&gt;167848&lt;/ulink&gt;], [&lt;ulink linkID="237778" linkType="reference"&gt;237778&lt;/ulink&gt;]. Its development was discontinued in 1997 [&lt;ulink linkID="353811" linkType="reference"&gt;353811&lt;/ulink&gt;]. The compound is a partial agonist of D1, D2 and D3 receptors, with particular affinity for D3 [&lt;ulink linkID="228526" linkType="reference"&gt;228526&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Parke-Davis has released results (99th American Society of Clinical Pharmacology and Therapeutics meeting, 1998) of three PK studies conducted with CI-1007, a dopamine D2 and D3 agonist with mild extrapyramidal side-effects. The first study was a placebo-controlled, crossover trial designed to evaluate the effects of CI-1007 as a single, oral dose of 0.5, 1, 2.5, 5, 10 or 15 mg (four subjects per dose group) plus placebo. The second study was a parallel group, double-blind, dose-escalation trial conducted in six healthy volunteers and the third study evaluated CI-1007 (5, 10 and 15 mg doses) in 16 schizophrenic patients. The first study was terminated at the 15 mg dose due to adverse events. An increase in growth hormone and decrease in serum prolactin levels was observed in all three trials. A safety and tolerability study in CYP2D6 poor metabolizers was underway.&lt;/para&gt;&lt;para&gt;CI-1007 is a lipophilic compound with moderate bioavailability and high hepatic clearance in animals. It readily penetrates the blood-brain barrier and causes only mild extrapyramidal side-effects in the monkey model.&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><ExpertReview>&lt;para&gt;Dr S Beckett, Department of Physiology and Pharmacology, &lt;ulink linkType="Company" linkID="20640"&gt;Nottingham University&lt;/ulink&gt;, UK&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;17 November 1998&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt;, a 1,2,3,6-tetrahydro-phenyl-1-((arylycyclohexenyl)alkyl) pyridine, is a partial dopamine agonist with preferential affinity for D2 and D3 autoreceptors [&lt;ulink linkType="reference" linkID="167848"&gt;167848&lt;/ulink&gt;]. Its ability to selectively reduce striatal dopamine activity [&lt;ulink linkType="reference" linkID="162150"&gt;162150&lt;/ulink&gt;] has led to its development as an antipsychotic, aimed at the treatment of schizophrenic-like disease states, for which it is now in phase II trials. The lack of extrapyramidal side-effects encountered with other dopamine antipsychotics [&lt;ulink linkType="reference" linkID="191087"&gt;191087&lt;/ulink&gt;] may provide a significant factor in the use of this compound in the clinic.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;The structure-activity relationship of several 1,2,3,6-tetrahydro-phenyl-1-((arylycyclohexenyl)alkyl) pyridine analogs has been assessed in terms of their dopaminergic activity. The most active configuration is obtained when the cyclohexane group had a 1,3 substitution pattern connected via a single methyl chain [&lt;ulink linkType="reference" linkID="167848"&gt;167848&lt;/ulink&gt;]. The (R)-(+)-enantiomer (&lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt;) has the highest intrinsic activity, with an IC50 at rat striatal D2 dopamine receptors of 53 nM compared with 112 and 113 nM for the (RS) and (S) forms, respectively [&lt;ulink linkType="reference" linkID="167848"&gt;167848&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;In vitro binding data reveal that &lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt; displays preferential affinity for cloned human D2L receptors (Ki = 25 nM) and D3 receptors (Ki = 16.6 nM) with a lower affinity for D4 receptors (Ki = 90.9 nM). It has moderate affinity for 5-HT1A, 5-HT2 and alpha-2 adrenergic receptors, and negligible affinity for D1 and alpha-1 adrenergic receptors [&lt;ulink linkType="reference" linkID="214375"&gt;214375&lt;/ulink&gt;]. Functionally, &lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt;, antagonizes forskolin-induced cyclic AMP increases in cells which express the D2L receptor with about half the intrinsic activity of the full agonist, quinperole [&lt;ulink linkType="reference" linkID="143188"&gt;143188&lt;/ulink&gt;]. As expected it decreases DA release in the striatum and nucleus accumbens [&lt;ulink linkType="reference" linkID="162150"&gt;162150&lt;/ulink&gt;] as well as reducing markers of DA synthesis and metabolism. This action appears to be selective as &lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt; has no effect on acetylcholine, norepinephrine levels or 5-HT release [&lt;ulink linkType="reference" linkID="214375"&gt;214375&lt;/ulink&gt;]. Electrophysiological studies reveal that &lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt; decreases the activity of substantia nigra DA neurons [&lt;ulink linkType="reference" linkID="191087"&gt;191087&lt;/ulink&gt;], suggesting a presynaptic site of action. This is endorsed by the finding that &lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt; inhibition of locomotor activity was not accompanied by stereotypy, which indicates a lack of postsynaptic effect [&lt;ulink linkType="reference" linkID="191087"&gt;191087&lt;/ulink&gt;]. Marginal postsynaptic DA antagonist effects have been suggested by comparison of apomorphine stimulated behaviors with spontaneous locomotor activity which is the profile expected from a partial agonist [&lt;ulink linkType="reference" linkID="191087"&gt;191087&lt;/ulink&gt;]. Of particular interest is the observation that whilst &lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt; inhibits Sidman avoidance responding in a similar way to known antipsychotics, it only induces mild extrapyramidal dysfunction [&lt;ulink linkType="reference" linkID="191087"&gt;191087&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt; failed to significantly inhibit footshock-induced ultrasonic vocalization in rats indicating a lack of anxiolytic effect [&lt;ulink linkType="reference" linkID="280112"&gt;280112&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt; is metabolized to hydroxylated [&lt;ulink linkType="reference" linkID="199417"&gt;199417&lt;/ulink&gt;] and sulfated [&lt;ulink linkType="reference" linkID="251049"&gt;251049&lt;/ulink&gt;] products which are detectable using HPLC [&lt;ulink linkType="reference" linkID="251049"&gt;251049&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="251048"&gt;251048&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="199417"&gt;199417&lt;/ulink&gt;]. Of these, only the hydroxylated metabolite, PD-147693, has appreciable pharmacological activity [&lt;ulink linkType="reference" linkID="251058"&gt;251058&lt;/ulink&gt;]. Compared to the parent compound, the metabolite has similar effects on inhibition of DA neuron firing and behavioral avoidance tests, although active doses of &lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt; result in plasma metabolite concentrations which are below active levels. This negates the contribution of metabolite effects to the overall effect of &lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="251048"&gt;251048&lt;/ulink&gt;]. Pharmacokinetically the actions of &lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt; and the active hydroxylated metabolite appear to be linearly related to dose [&lt;ulink linkType="reference" linkID="305926"&gt;305926&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No toxic effects have been reported.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;Safety, tolerance and pharmacokinetics parameters have been established for &lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="240102"&gt;240102&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="240309"&gt;240309&lt;/ulink&gt;]. Initial results from phase I clinical trials indicate that &lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt; is generally well-tolerated over a dose range (0.5 to 20 mg/day) [&lt;ulink linkType="reference" linkID="284141"&gt;284141&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="305926"&gt;305926&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="284141"&gt;284141&lt;/ulink&gt;] and with repeated doses (9 doses/24 h). &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt; is currently in phase II clinical trials. In-patient bridging studies have demonstrated the safety and tolerability in schizophrenic inpatients [&lt;ulink linkType="reference" linkID="305926"&gt;305926&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="272219"&gt;272219&lt;/ulink&gt;]. However, larger subject groups and longer study durations will be needed to provide convincing evidence of therapeutic benefit. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side-effects and Contraindications&lt;/subtitle&gt;Moderate adverse side-effects have been reported which are ascribed to the drugs extrapyramidal actions. These include postural hypotension, nausea and vomiting which appear to be related to initial high doses [&lt;ulink linkType="reference" linkID="305926"&gt;305926&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="240102"&gt;240102&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="284141"&gt;284141&lt;/ulink&gt;]. Such side-effects are consistent with those seen for other dopamine autoreceptor agonists such as, &lt;ulink linkType="Drug" linkID="11471"&gt;preclamol&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4151"&gt;pramipexole&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="240102"&gt;240102&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;Control of brain dopamine levels remains the primary target of antipsychotic therapy. Dopamine antagonist-based neuroleptics are not effective in all schizophrenics and have associated deleterious extrapyramidal side-effects. The pharmacological profile of &lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt; is one of a relatively selective D2/D3 autoreceptor agonist with negligible affinity for other neurotransmitter systems. Presynaptic attenuation of dopaminergic transmission therefore represents a beneficial approach to avoiding motor disturbances. Preclinical data have endorsed the potential efficacy of &lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt;, and ongoing phase II clinical trials continue to support these findings. &lt;ulink linkType="Drug" linkID="8148"&gt;PD-143188&lt;/ulink&gt; appears to be generally well-tolerated with extrapyramidal side-effects confined to initial high doses.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20805">Parke-Davis &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="282">Psychotic disorder</Indication><StatusDate>2000-01-31T00:00:00.000Z</StatusDate><Source id="353811" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20805">Parke-Davis &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="299">Schizophrenia</Indication><StatusDate>2000-01-31T00:00:00.000Z</StatusDate><Source id="353811" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20805">Parke-Davis &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication><StatusDate>1996-11-01T00:00:00.000Z</StatusDate><Source id="237778" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20805">Parke-Davis &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20805">Parke-Davis &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20805">Parke-Davis &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="299">Schizophrenia</Indication></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00637"><Name>Dopamine receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>c1ccc(cc1)C2=CCN(CC2)C[C@@H]3CCC=C(C3)c4ccccc4</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="498196" number="WO-09608473" title="Improved process for (R)-(+)-1,2,3,6-tetrahydro-4-phenyl-1-[(3-phenylcyclohexen-1-yl)methyl]pyridine, a central nervous system agent"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>